SPAC Berto (TACO) announces LOI with OnMed for potential merger

Rhea-AI Filing Summary

Berto Acquisition Corp. announced that it and OnMed LLC entered into a non-binding letter of intent on October 29, 2025 for a potential business combination.

The LOI does not guarantee a deal. Any transaction would require completion of due diligence, negotiation and execution of a definitive agreement, satisfaction of agreed conditions, board and equity holder approvals, regulatory approvals, and other customary steps. The companies also cautioned that timing and terms may change or the transaction may not occur.

The disclosure was furnished under Item 7.01 and not deemed filed. If a definitive agreement is signed, Berto or a newly formed holding company will prepare and file a registration statement that includes a proxy statement/prospectus with the SEC, which would be mailed to Berto’s shareholders.

Insights

SPAC M&A analyst

Non-binding LOI signals intent, not a completed deal.

Berto Acquisition Corp. and OnMed disclosed a non-binding LOI for a potential merger. In SPAC processes, an LOI outlines key terms and exclusivity expectations but leaves material points open until a definitive agreement is executed.

Closing would depend on due diligence, finalized terms, shareholder approvals, and regulatory clearances. The companies expressly note there is no assurance a transaction will be consummated, and terms or timing may change.

If the parties proceed to a definitive agreement, a registration statement with a proxy statement/prospectus will be filed with the SEC for shareholder voting. Actual impact will hinge on the final terms and approvals disclosed in subsequent filings.

false 0002033122 0002033122 2025-10-29 2025-10-29 0002033122 TACOU:UnitsConsistingOfOneOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2025-10-29 2025-10-29 0002033122 TACOU:OrdinarySharesParValue0.0001ParValueMember 2025-10-29 2025-10-29 0002033122 TACOU:WarrantsEntitlingTheHolderToPurchaseOneOrdinaryShareParValue0.0001PerShareMember 2025-10-29 2025-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 29, 2025

BERTO ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-42620		99-4250815
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1180 North Town Center Drive, Suite 100
Las Vegas, Nevada 89144

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (702) 781-4313

Not Applicable
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Units, consisting of one ordinary share, $0.0001 par value, and one-half of one redeemable warrant		TACOU		The Nasdaq Stock Market LLC
Ordinary shares, par value $0.0001 per share		TACO		The Nasdaq Stock Market LLC
Warrants entitling the holder to purchase one ordinary share, par value $0.0001 per share		TACOW		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On October 29, 2025, Berto Acquisition Corp., a special purpose acquisition company (“Berto”), and OnMed LLC, a developer of healthcare infrastructure solutions (“OnMed”), issued a joint press release announcing that they have entered into a non-binding letter of intent for a potential business combination. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

No assurances can be made that Berto and OnMed will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to the completion of due diligence, the negotiation of a definitive agreement providing for the proposed business combination, satisfaction of the conditions negotiated therein, board and equity holder approval, regulatory approvals, and other customary conditions.

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings.

Additional Information and Where to Find It

If a definitive agreement is entered into in connection with the proposed business combination, Berto or a newly formed holding company will prepare a registration statement, including a proxy statement/prospectus, to be filed with the U.S. Securities and Exchange Commission (“SEC”). The proxy statement/prospectus will be mailed to Berto’s shareholders. Berto urges investors and other interested persons to read, when available, the proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the proposed business combination. Such persons can also read Berto’s reports filed with the SEC for a description of the security holdings of its officers and directors and their respective interests as security holders in the consummation of the transactions described herein. The proxy statement/prospectus, once available, and Berto’s reports can be obtained, without charge, at the SEC’s website (http://www.sec.gov).

Participants in the Solicitation

OnMed and Berto and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Berto’s shareholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Berto’s directors and officers in Berto’s reports filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Berto’s shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available. Information concerning the interests of OnMed’s and Berto’s participants in the solicitation, which may, in some cases, be different than those of their respective equityholders generally, will be set forth in the proxy statement/prospectus relating to the proposed business combination when it becomes available.

1

Forward-Looking Statements:

This Current Report on Form 8-K and the exhibit hereto include “forward-looking statements” with respect to Berto and OnMed. The expectations, estimates, and projections of the businesses of OnMed and Berto may differ from their actual results and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to future performance and anticipated financial impacts of the proposed transaction, the satisfaction of the closing conditions to the proposed transaction, and the timing of the completion of the proposed transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of OnMed and Berto and are difficult to predict. In addition to the factors described in the exhibit hereto under the heading “Details of the Proposed Transaction”, factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the negotiations and any subsequent definitive agreements with respect to the proposed business combination, and the possibility that the terms and conditions set forth in any definitive agreements with respect to the proposed business combination may differ materially from the terms and conditions set forth in the letter of intent; (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed business combination and any definitive agreements with respect thereto; (3) the inability to complete the proposed transaction, including due to failure to obtain approval of the shareholders of OnMed and Berto or other conditions to closing; (4) the inability to obtain or maintain the listing of the post-acquisition company’s common stock on Nasdaq, the New York Stock Exchange, or another national securities exchange following the proposed transaction; (5) the risk that the proposed transaction disrupts current plans and operations as a result of the announcement and consummation of the proposed transaction; (6) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (7) costs related to the proposed transaction; (8) changes in applicable laws or regulations; and (9) other risks and uncertainties included in documents filed or to be filed with the SEC by OnMed and Berto. The foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. OnMed and Berto do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Past performance by OnMed’s or Berto’s management teams and their respective affiliates is not a guarantee of future performance. Therefore, you should not place undue reliance on the historical record of the performance of OnMed’s or Berto’s management teams or businesses associated with them as indicative of future performance of an investment or the returns that OnMed or Berto will, or are likely to, generate going forward.

No Offer or Solicitation

This Current Report on Form 8-K and the exhibit hereto shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction. This Current Report on Form 8-K and the exhibit hereto shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

2

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated October 29, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BERTO ACQUISITION CORP.
	By:	/s/ Harry L. You
		Name:	Harry L. You
		Title:	Executive Chairman
Dated: October 29, 2025

4

FAQ

What did Berto Acquisition Corp. (TACO) announce?

Berto and OnMed LLC entered into a non-binding letter of intent for a potential business combination on October 29, 2025.

Is the LOI between Berto (TACO) and OnMed binding?

No. The LOI is non-binding and provides no assurance a definitive agreement will be reached or a transaction completed.

What approvals would a Berto–OnMed transaction require?

It would require due diligence, a definitive agreement, board and equity holder approvals, regulatory approvals, and other customary conditions.

Will there be a proxy statement/prospectus for Berto (TACO) shareholders?

If a definitive agreement is signed, Berto or a holding company will file a registration statement including a proxy statement/prospectus with the SEC.

Where can investors find future documents on the potential Berto–OnMed deal?

Documents will be available on the SEC’s website at http://www.sec.gov.

What exchanges are Berto’s securities listed on?

Berto’s units (TACOU), ordinary shares (TACO), and warrants (TACOW) are listed on The Nasdaq Stock Market LLC.